Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Poznan University of Medical Sciences, Poznan, Poland



Survival: 10.4 months
   
Toxicity Grade: 5
   
Treatments: Chemotherapy
   
Drugs:
Country: Poland
   
City/State/Province: Poznan
   
Hospital: Poznan University of Medical Sciences
   
Journal: Link
   
Date: 10/2012

Description:
Patients:
This phase 3 study involved platinum-pretreated patients with advanced or metastatic non-squamous non-small-cell lung cancer patients who were divided into two separate treatment groups. Group A had 457 patients with an average age of 59.6 years and 65.6% male. Group B consisted of 456 patients with an average age of 59.6 years and 66.9% male.

Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel and the biologic therapy aflibercept, which is an inhibitor of the VEGF protein that interferes with tumor growth.

Patients in group B were treated with docetaxel and a placebo.

Toxicities:
Treatment-related deaths due to neutropenic infections and pulmonary embolism were reported in group A. Grade 3 or higher kidney toxicity, fatigue, and stomatitis (inflammation of the lining of the GI tract) were also reported.

In group B, there were treatment-related deaths due to neutropenic infection and arterial thromboembolisms (blood clots). Grade 3 or higher fatigue and shortness of breath were also reported.

Results:
The median overall survival was 10.1 months for group A and 10.4 months for group B.

Support:
This study was supported by Sanofi, makers of aflibercept.

Correspondence: Dr. Rodryg Ramlau; email: rramlau@onet.eu

E-mail to a Friend Email Physician More Information